SARS-CoV-2 spike protein mutations: Difference between revisions
Jump to navigation
Jump to search
Eric Martz (talk | contribs) No edit summary |
Eric Martz (talk | contribs) No edit summary |
||
| Line 53: | Line 53: | ||
====B.1.617==== | ====B.1.617==== | ||
The defining mutations in B.1.617 include L452R, P681R, and E484Q. '''L452R''' is present in B.1.429 the US "California" lineage, and confers resistance to convalescent serum antibodies<ref name="convalescent" />. '''P681R''' occurs in B.1.1.7, is in the [[SARS-CoV-2 spike protein priming by furin|furin cleavage site]] and is suspected of increasing contagiousness<ref name="617who" />. '''E484Q''' is similar to E484K, present in the "South African" lineage B.1.351 / 501Y.V2, and is thought to contribute to evasion of immunity<ref name="617who" />. | The defining mutations in B.1.617 include L452R, P681R, and E484Q. '''L452R''' is present in B.1.429 the US "California" lineage, and confers resistance to convalescent serum antibodies<ref name="convalescent" />. '''P681R''' occurs in B.1.1.7, is in the [[SARS-CoV-2 spike protein priming by furin|furin cleavage site]] and is suspected of increasing contagiousness<ref name="617who" />. '''E484Q''' is similar to E484K, present in the "South African" lineage B.1.351 / 501Y.V2, and is thought to contribute to evasion of immunity<ref name="617who" /><ref name="greaney">PMID: 33592168</ref>. | ||
===Vaccine Effectiveness Under Investigation=== | ===Vaccine Effectiveness Under Investigation=== | ||